BioSpace News Archive

TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B financing.

Imperial College London’s Professor of Hepatology, Mark Thursz, has been appointed to the Scientific Advisory Board of HepaTx (the SAB), a biotechnology company focused on cell therapy liver diseases

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17th- 20th, 2023.

PepGen Inc. (Nasdaq: PEPG) today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20th at 8:00am EDT.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results.

Abcam plc, a global leader in the supply of life science research tools, provides the following preliminary trading update for the quarter ending 31 March 2023.

Infinity Pharmaceuticals, Inc. today announced upcoming presentations including data on eganelisib by Infinity’s collaborator, Professor Judith A. Varner of the UCSD Moores Cancer Center, La Jolla, California, at the 2023 Annual Meeting of the American Association of Cancer Research (AACR) to be held April 14 - 19, 2023 in Orlando, Florida.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs, announced annual financial results for the year ended December 31, 2022.

Exelixis, Inc. announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes.